As of 2024, Matthew W. Emmens holds more than $101 million in Vertex Pharmaceuticals shares, indicating a strong personal investment in the company. His holdings peaked significantly during his tenure as CEO, especially when he earned over $5 million in...

As of 2024, Matthew W. Emmens holds more than $101 million in Vertex Pharmaceuticals shares, indicating a strong personal investment in the company. His holdings peaked significantly during his tenure as CEO, especially when he earned over $5 million in 2011, largely due to performance bonuses. Notably, in 2010, he shifted focus away from stock options to emphasize cash compensation, which might have affected his wealth's composition. After his departure in 2012, his wealth remained heavily tied to Vertex shares, reflecting his long-term commitment. His insight and decisions during his leadership period directly influenced the company's share value.